| INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP (NCT06144840) | Tanabe Pharma America, Inc. | 2023-12-11 |
| Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects (NCT05241535) | Tanabe Pharma America, Inc. | 2022-01-12 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS (NCT05151471) | Tanabe Pharma America, Inc. | 2022-01-11 |
| Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury (NCT04683848) | Tanabe Pharma America, Inc. | 2021-08-27 |
| Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) (NCT05005975) | Tanabe Pharma America, Inc. | 2021-08-10 |
| Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects (NCT04793295) | Tanabe Pharma America, Inc. | 2021-03-23 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis (NCT04440592) | Tanabe Pharma America, Inc. | 2021-02-05 |
| PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function (NCT04656795) | Tanabe Pharma America, Inc. | 2020-12-02 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria (NCT04402489) | Tanabe Pharma America, Inc. | 2020-06-01 |
| Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury (NCT04096950) | Tanabe Pharma America, Inc. | 2020-04-19 |
| Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function (NCT04116476) | Tanabe Pharma America, Inc. | 2019-08-01 |
| Safety and Efficacy Study of MT-2990 in Women With Endometriosis (NCT03840993) | Tanabe Pharma America, Inc. | 2019-01-15 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects (NCT03809039) | Tanabe Pharma America, Inc. | 2019-01-15 |
| Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor (NCT03688022) | Tanabe Pharma America, Inc. | 2018-10-25 |
| Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria (NCT03520036) | Tanabe Pharma America, Inc. | 2018-07-05 |
| Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms (NCT03541200) | Tanabe Pharma America, Inc. | 2018-04-18 |
| Mass Balance Study With MT-7117 (NCT03503266) | Tanabe Pharma America, Inc. | 2018-03-23 |
| Mass Balance Study With MT-8554 (NCT03381404) | Tanabe Pharma America, Inc. | 2017-12-19 |
| MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women (NCT03291067) | Tanabe Pharma America, Inc. | 2017-10-09 |